Neelima Vidula, M.D. is a breast medical oncologist at Massachusetts General Hospital (MGH). She strives to provide outstanding patient care, and incorporate the latest data and newest therapies in treatment plans for patients. Dr. Vidula completed medical school and residency in internal medicine at Northwestern University in Chicago, IL, and a fellowship in hematology and medical oncology at the University of California San Francisco in San Francisco, CA.
Dr. Vidula is the principal investigator of many early phase clinical trials studying novel agents for patients with breast cancer. Among these trials, she is the national co-principal investigator of a multi-center study she designed with immunotherapy and chemotherapy for chest wall disease, which she is leading at multiple sites across the country including MGH through the Translational Breast Cancer Research Consortium. She was recently awarded a prestigious Pfizer ASPIRE award for a study she designed to evaluate a PARP inhibitor in patients with somatic BRCA mutant metastatic breast cancer. Dr. Vidula also performs clinical research evaluating the impact of biomarkers on therapy response and patient outcomes, and conducts research in precision medicine using cell-free DNA and tumor genotyping. She has presented her research at several national and international meetings, and published articles in high-impact journals. She also enjoys teaching medical students, residents, and fellows.